| 英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
|---|---|---|---|---|---|---|
|
APETx2
|
713544-47-9 |
APETx2
|
APETX2毒素肽
|
C196H280N54O61S6 |
4561 | |
|
PKI-587
|
1197160-78-3 |
N-[4-[[4-(二甲基氨基)-1-哌啶基]羰基]苯基]-N'-[4-[4,6-二(4-吗啉基)-1,3,5-三嗪-2-基]苯基]脲
|
CS-46;GEDATOLISIB;PF-05212384;PF-05212384;PKI587;PKI 587;PKI-587;PF-05212384;PF-05212384;N-[4-[[4-(二甲基氨基)-1-哌啶基]羰基]苯基]-N'-[4-[4,6-二(4-吗啉基)-1,3,5-三嗪-2-基]苯基]脲;GEDATOLISIB;PKI-587;GEDATOLISIB (PF-05212384,PKI-587);PKI-587
|
C32H41N9O4 |
615.72584 | |
|
Tozasertib
|
639089-54-6 |
陶扎色替
|
N-[4-[[4-(4-甲基-1-哌嗪基)-6-[(5-甲基-1H-吡唑-3-基)氨基]-2-嘧啶基]硫]苯基]环丙烷甲酰胺;陶扎色替;VX680;MK0457;VX 680 (MK 0457;TOZASERTIB);TOZASERTIB;MK-0457;MK0457;VX680;VX 680;MK 0457;陶扎色替VX-860;VX-680;MK-0457,陶扎色替;陶扎色替TOZASERTIB;CS-177
|
C23H28N8OS |
464.59 | |
|
cabozantinib
|
849217-68-1 |
卡博替尼(CABOZANTINIB)
|
N-(4-((6,7-二M乙羟喹啉-4-基)氧基)苯基)-N-(4-氟苯基)环丙烷-1,1-二甲酰胺;苹果酸盐CABOZANTINIB;苹果酸盐 XL-184;卡博替尼184
|
C28H24FN3O5 |
502 | 692-846-8 |
|
N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea
|
623142-96-1 |
N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲
|
KI20227;KI-20227;KI 20227;CS-1094;KI20227;KI 20227;N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲
|
C24H24N4O5S |
480.543 | 200-258-5 |
|
Conivaptan Hydrochloride
|
168626-94-6 |
盐酸考尼伐坦
|
考尼伐坦;盐酸考尼代坦;[1,1'-联苯]-2-甲酰胺,N-[4-[(4,5-二氢-2-甲基咪唑并[4,5-D〕[4]苯并氮杂-6(1H)-基)羰基]苯基]盐酸盐;考尼伐坦盐酸盐;N-[4-(2-甲基-4,5-二氢-3H-咪唑并[4,5-D][1]苯并氮杂卓-6-甲酰基)苯基]-2-苯基苯甲酰胺盐酸盐;盐酸考尼伐坦;盐酸考尼法坦
|
C32H26N4O2.HCl |
535.04 | 1312995-182-4 |
|
Canertinib di hydrochloride
|
289499-45-2 |
卡纽替尼二盐酸盐
|
盐酸卡奈替尼;CANERTINIB;CI-1033 DIHYDROCHLORIDE;PD-183805 DIHYDROCHLORIDE;CI1033 DIHYDROCHLORIDE;CI 1033 DIHYDROCHLORIDE;PD183805 DIHYDROCHLORIDE;PD 183805 DIHYDROCHLORIDE;N-[4-[(3-氯-4-氟苯基)氨基]-7-(3-吗啉-4-基丙氧基)喹唑啉-6-基]丙-3-烯酰胺二盐酸盐;卡纽替尼二盐酸盐;卡那替尼盐酸盐;卡奈替尼,卡纽替尼;卡纽替尼二盐
|
C24H27Cl3FN5O3 |
558.86 | |
|
Foretinib (GSK1363089, XL880)
|
849217-64-7 |
Foretinib (GSK136389)
|
XL-880;EXEL-2880;XL 880;(试剂)FORETINIB (GSK1363089,XL880);1-N'-[3-FLUORO-4-({6-METHOXY-7-[3-(MORPHOLIN-4-YL)PROPOXY]QUINOLIN-4-YL}OXY)PHENYL]-1-N-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE;XL-880;GSK089;EXEL-2880;XL 880;GSK-089;GSK 1363089;GSK-1363089;N-[3-氟-4-[[6-甲氧基-7-[[3-(吗啉-4-基)丙基]氧]喹啉-4-基]氧]苯基]-N'-(4-氟苯基)环丙烷-1,1-二甲酰胺;FORETINIB GLAXOSMITHKLINE PAPILLARY RENAL CELL CARCINOMA PHASE IIRSCH. TRIANGLE PARK,NC (SEE ALSO HEAD;NECK)(888)825-5249;GSK1363089;FORETINIB;EXEL-2880
|
C34H34F2N4O6 |
632.653766 | |
|
KL001
|
309928-48-1 |
N-(3-(9H-咔唑-9-基)-2-羟基丙基)-N-(呋喃-2-基甲基)甲烷磺酰胺
|
N-(3-(9H-咔唑-9-基)-2-羟基丙基)-N-(呋喃-2-基甲基)甲烷磺酰胺
|
C21H22N2O4S |
398.48 | |
|
doramapimod
|
285983-48-4 |
1-[2-(4-甲基苯基)-5-叔丁基吡唑-3-基]-3-[4-(2-吗啉-4-基乙氧基)萘-1-基]脲
|
达马莫德;多马莫德;度马莫德;脲,N-[3-(1,1-二甲基乙基)-1-(4-甲基苯基)-1H-吡唑-5-基]-N'-[4-[2-(4-吗啉基)乙氧基]-2-萘基]-
|
C31H37N5O3 |
527.66 | 1308068-626-2 |
|
BMX-IN-1
|
1431525-23-3 |
N-[2-甲基-5-[9-[4-[(甲基磺酰基)氨基]苯基]-2-氧代苯并[H]-1,6-萘啶-1(2H)-基]苯基]-2-丙烯酰胺
|
N-[2-甲基-5-[9-[4-[(甲基磺酰基)氨基]苯基]-2-氧代苯并[H]-1,6-萘啶-1(2H)-基]苯基]-2-丙烯酰胺;BMX KINASE INHIBITOR;N-(2-METHYL-5-(9-(4-(METHYLSULFONAMIDO)PHENYL)-2-OXOBENZO[H][1;6]NAPHTHYRIDIN-1(2H)-YL)PHENYL)ACRYLAMIDE
|
C29H24N4O4S |
524.59026 | |
|
Arformoterol tartrate
|
200815-49-2 |
酒石酸福莫特罗
|
酒石酸福莫特罗;N-[2-羟基-5-[(1R)-1-羟基-2-[(1R)-2-(4-甲氧基苯基)-1-甲基乙基]氨基]乙基]苯基]甲酰胺-L-(+)-酒石酸盐;酒石酸阿福莫特罗;酒石酸阿福特罗;酒石酸阿福特罗溶液,100PPM
|
C19H24N2O4.C4H6O6 |
494.494 | 200-589-5 |
|
Azoramide
|
932986-18-0 |
N-[2-[2-(4-氯苯基)-4-噻唑基]乙基]丁酰胺
|
N-[2-[2-(4-氯苯基)-4-噻唑基]乙基]丁酰胺;N-[2-[2-(4-氯苯基)-4-噻唑基]乙基]丁酰胺;CS-1554;N-(2-(2-(4-氯苯基)噻唑-4-基)乙基)丁酰胺
|
C15H17ClN2OS |
308.82628 | |
|
ranitidine hydrochloride
|
66357-59-3 |
盐酸雷尼替丁
|
N'-甲基-N-[2-[[[5-[(二甲氨基)甲基]-2-呋喃基]-甲基]硫代]乙基]-2-硝基-1,1-乙烯二胺盐酸盐;盐酸雷尼替丁;N-[2-[[[5-[(二甲基氨基)甲基]-2-呋喃基]甲基]硫代]乙基]-N'-甲基-2-硝基-1,1-乙烯二胺盐酸盐;盐酸雷尼替丁(CAS号:66357-59-3);盐酸雷尼替丁,99%;雷尼替丁盐酸盐(USP美国药典标准品);雷尼替丁盐酸盐,98.1%(LC&T;盐酸雷尼替丁(标准品)
|
C13H23CLN4O3S;C13H22N4O |
350.86 | 266-333-0; 275-207-4 |
|
Ramelteon
|
196597-26-9 |
雷美替胺
|
雷美替胺;瑞美替胺;拉梅尔通;瑞美替胺;瑞美替昂-D5;瑞美替胺196597-26-10;雷美替胺
|
C16H21NO2 |
259.34 | 200-835-2 |
|
ABT-751
|
141430-65-1 |
N-[2-[(4-羟基苯基)氨基]-3-吡啶基]-4-甲氧基苯磺酰胺
|
ABT751;ABT 751;E7010;E-7010;E 7010;CS-1806;CS-505;N-[2-[(4-羟基苯基)氨基]吡啶-3-基]-4-甲氧基苯磺酰胺;ABT-751 (E7010);ABT751;ABT 751;N-[2-[(4-羟基苯基)氨基]-3-吡啶基]-4-甲氧基苯磺酰胺
|
C18H17N3O4S |
371.41028 | 256-495-9 |
|
DEL-22379
|
181223-80-3 |
N-[2,3-二氢-3-[(5-甲氧基-1H-吲哚-3-基)亚甲基]-2-氧代-1H-吲哚-5-基]-1-哌啶丙酰胺
|
CS-2171;DEL-22379,一种ERK二聚化抑制剂;DEL22379;DEL 22379;DEL-22379;N-[2,3-二氢-3-[(5-甲氧基-1H-吲哚-3-基)亚甲基]-2-氧代-1H-吲哚-5-基]-1-哌啶丙酰胺
|
C26H28N4O3 |
444.52552 | |
|
TRC051384
|
867164-40-7 |
867164-4-7
|
TRC 051384;TRC-051384
|
C25H31N5O4 |
465.554 | |
|
2-[1-benzyl-5-[4-(trifluoromethoxy)phenyl]indol-3-yl]-2-oxo-acetic aci d
|
393105-53-8 |
ALPHA-氧代-1-(苯基甲基)-5-[4-(三氟甲氧基)苯基]-1H-吲哚-3-乙酸
|
ALPHA-氧代-1-(苯基甲基)-5-[4-(三氟甲氧基)苯基]-1H-吲哚-3-乙酸;TIPLAXTININ(PAI-039);TIPLAXTININ;PAI039;PAI 039;ALPHA-氧代-1-(苯基甲基)-5-[4-(三氟甲氧基)苯基]-1H-吲哚-3-乙酸>98%
|
C24H16F3NO4 |
439.38334 | |
|
IRAK-1-4 Inhibitor I
|
509093-47-4 |
IRAK-1-4 抑制剂 I
|
CS-1991;IRAK-1-4 抑制剂 I;IRAK-1-4 INHIBITOR I ;INTERLEUKIN-1 RECEPTOR-ASSOCIATED-KINASE-1;4 INHIBITOR;IRAK-1;4 抑制剂
|
C20H21N5O4 |
395.417 |
药智官方微信
药智官方微博
